Hoi Kin Wong1, Kwok Leung Ong2, Ching-Lung Cheung3, Bernard M Y Cheung4. 1. Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong. 2. Centre for Vascular Research, University of New South Wales, Sydney, Australia; Faculty of Medicine, University of Sydney, Sydney, NSW, Australia. 3. Department of Medicine, University of Hong Kong, Hong Kong. 4. Department of Medicine, University of Hong Kong, Hong Kong. Electronic address: mycheung@hku.hk.
Abstract
PURPOSE: Changes in relation to drug treatment to various control targets for diabetes were studied using the National Health and Nutrition Examination Survey, 1999-2010. METHODS: Data on 3094 participants aged 20 years or older with diagnosed type II diabetes were analyzed. Use of medications for lowering glucose, blood pressure, and lipids in the past month was assessed by questionnaire. Data from two survey cycles were combined together to produce estimates for each 4-year period. RESULTS: Usage of metformin increased from 34.8% to 53.8% and was the most prevalent medications during this period (P < .001), and half of subjects taking metformin could achieve glycated hemoglobin less than 7.0% in 2007-2010. Dipeptidyl peptidase-4 inhibitors were used by 7.4% of participants in 2007-2010. Usage of angiotensin receptor blockers and beta-blockers increased significantly from 7.4% to 21.4% and from 15.3% to 31.8%, respectively from 1999 to 2010 (P ≤ .001). A total of 64.7% of participants could attain blood pressure control by 2007-2010. Usage of statins doubled in 1999-2010 and 52.2% of subjects took statins by 2007-2010 (P < .001). CONCLUSIONS: Metformin is the first-line drug for diabetes while dipeptidyl peptidase-4 inhibitors started to be used since 2007. Blood pressure control improved in 1999-2010 partly due to increased drug prescriptions. Although statins were widely used about half of the participants did not take them.
PURPOSE: Changes in relation to drug treatment to various control targets for diabetes were studied using the National Health and Nutrition Examination Survey, 1999-2010. METHODS: Data on 3094 participants aged 20 years or older with diagnosed type II diabetes were analyzed. Use of medications for lowering glucose, blood pressure, and lipids in the past month was assessed by questionnaire. Data from two survey cycles were combined together to produce estimates for each 4-year period. RESULTS: Usage of metformin increased from 34.8% to 53.8% and was the most prevalent medications during this period (P < .001), and half of subjects taking metformin could achieve glycated hemoglobin less than 7.0% in 2007-2010. Dipeptidyl peptidase-4 inhibitors were used by 7.4% of participants in 2007-2010. Usage of angiotensin receptor blockers and beta-blockers increased significantly from 7.4% to 21.4% and from 15.3% to 31.8%, respectively from 1999 to 2010 (P ≤ .001). A total of 64.7% of participants could attain blood pressure control by 2007-2010. Usage of statins doubled in 1999-2010 and 52.2% of subjects took statins by 2007-2010 (P < .001). CONCLUSIONS:Metformin is the first-line drug for diabetes while dipeptidyl peptidase-4 inhibitors started to be used since 2007. Blood pressure control improved in 1999-2010 partly due to increased drug prescriptions. Although statins were widely used about half of the participants did not take them.
Authors: Tracy L Kinsey; Til Stürmer; Charles Poole; Kenneth J Rothman; Robert J Glynn Journal: Pharmacoepidemiol Drug Saf Date: 2018-12-19 Impact factor: 2.890
Authors: Nicola Veronese; Cyrus Cooper; Jean-Yves Reginster; Marc Hochberg; Jaime Branco; Olivier Bruyère; Roland Chapurlat; Nasser Al-Daghri; Elaine Dennison; Gabriel Herrero-Beaumont; Jean-François Kaux; Emmanuel Maheu; René Rizzoli; Roland Roth; Lucio C Rovati; Daniel Uebelhart; Mila Vlaskovska; André Scheen Journal: Semin Arthritis Rheum Date: 2019-01-11 Impact factor: 5.532
Authors: Kristen E Gray; Jodie G Katon; Eileen Rillamas-Sun; Lori A Bastian; Karin M Nelson; Andrea Z LaCroix; Gayle E Reiber Journal: Gerontologist Date: 2016-02
Authors: Matthew J Crowley; Maren K Olsen; Sandra L Woolson; Heather A King; Eugene Z Oddone; Hayden B Bosworth Journal: J Clin Hypertens (Greenwich) Date: 2015-09-15 Impact factor: 3.738
Authors: Eric Adua; Peter Roberts; Samuel Asamoah Sakyi; Francis Agyemang Yeboah; Albert Dompreh; Kwasi Frimpong; Enoch Odame Anto; Wei Wang Journal: Clin Transl Med Date: 2017-09-07
Authors: Carla I Mercado; Kai McKeever Bullard; Edward W Gregg; Mohammed K Ali; Sharon H Saydah; Giuseppina Imperatore Journal: Diabetes Care Date: 2021-06-14 Impact factor: 17.152